Home › Research › Tau biomarkers
The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function
Dowling NM, Johnson SC, Gleason CE, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative.. NeuroImage, 2014-10-29
Topic: Brain proteins, microglia and lab models
Plain-language summary
Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer's disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. But the temporal relationship between CSF, imaging markers of neural function, and cognition has not been described. Using a statistical mediation model, we examined relationships between cerebrospinal fluid (CSF) analytes (hyperphosphorylated tau (p-Tau(181p)), β-amyloid peptides 1-42 (Aβ(1-42)), total tau (t-Tau), and their ratios); change in cognitive function; and change in [18F]fluorodeoxyglucose (FDG) uptake using positron emission tomography (PET).
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 82 participants. This study used a statistical model to examine whether reduced brain glucose metabolism (measured by FDG PET) links cerebrospinal fluid Alzheimer biomarkers to changes in cognitive function. It is an observational cohort study, so it cannot show that any treatment targeting these markers would change cognition.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dowling, N. M., Johnson, S. C., Gleason, C. E., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative. (2015). The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage. https://doi.org/10.1016/j.neuroimage.2014.10.050
Vancouver
Dowling NM, Johnson SC, Gleason CE, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage. 2015. doi:10.1016/j.neuroimage.2014.10.050. PMID: 25450107.
BibTeX
@article{dowling2015-25450107,
author = {Dowling, N. M. and Johnson, S. C. and Gleason, C. E. and Jagust, W. J. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function}},
journal = {NeuroImage},
year = {2015},
doi = {10.1016/j.neuroimage.2014.10.050},
pmid = {25450107},
url = {https://doi.org/10.1016/j.neuroimage.2014.10.050}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- But the temporal relationship between CSF, imaging markers of neural function, and cognition has not been described.
- Using a statistical mediation model, we examined relationships between cerebrospinal fluid (CSF) analytes (hyperphosphorylated tau (p-Tau(181p)), β-amyloid peptides 1-42 (Aβ(1-42)), total tau (t-Tau), and their ratios); change in cognitive function; and change in [18F]fluorodeoxyglucose (FDG) uptake using positron emission tomography (PET).
- We hypothesized that a) abnormal CSF protein values at baseline, result in cognitive declines by decreasing neuronal glucose metabolism across time, and b) the role of altered glucose metabolism in the assumed causal chain varies by brain region and the nature of CSF protein alteration.
- Data from 412 individuals participating in Alzheimer's Disease Neuroimaging (ADNI) cohort studies were included in analyses.
Why it matters
This study used a statistical model to examine whether reduced brain glucose metabolism (measured by FDG PET) links cerebrospinal fluid Alzheimer biomarkers to changes in cognitive function. It is an observational cohort study, so it cannot show that any treatment targeting these markers would change cognition.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants82
- Evidence strengthModerate
How this study scored 56/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (NeuroImage) |
| Journal's citation record | 4 / 4 | NeuroImage: journal h-index 523 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 82 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 43 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 3 / 6 | Cited 4.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author William Jagust: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25450107) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neuroimage.2014.10.050
- PubMed: 25450107
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.